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Abstract
Background: Few reports of the utilization of an accurate, cost-effective means for measuring
HPV oncogene transcripts have been published. Several papers have reported the use of relative
quantitation or more expensive Taqman methods. Here, we report a method of absolute
quantitative real-time PCR utilizing SYBR-green fluorescence for the measurement of HPV E7
expression in cervical cytobrush specimens.
Results: The construction of a standard curve based on the serial dilution of an E7-containing
plasmid was the key for being able to accurately compare measurements between cervical samples.
The assay was highly reproducible with an overall coefficient of variation of 10.4%.
Conclusion: The use of highly reproducible and accurate SYBR-based real-time polymerase chain
reaction (PCR) assays instead of performing Taqman-type assays allows low-cost, high-throughput
analysis of viral mRNA expression. The development of such assays will help in refining the current
screening programs for HPV-related carcinomas.
Background
Infection with certain types of human papillomavirus
(HPV), while a necessary cause of cervical cancer, does not
guarantee an elevated risk of malignancy. An estimated
80% of all women will become infected with HPV at some
point in their lives [1]; however, few will develop dyspla-
sia of the cervix. Approximately 11% of those that develop
mild dysplasia or low-grade squamous intraepithelial
lesions (LSIL) will progress to severe dysplasia or high-
grade squamous intraepithelial lesions (HSIL), and an
equal fraction will further progress to invasive carcinoma
[2]. The challenge is determining which women are likely
to progress versus those who will spontaneously regress.
While screening with the Papanicolaou (Pap) test has
been effective in lowering cervical cancer rates in countries
with effective screening systems, it is still not sensitive and
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cancerous lesions.
Laboratory studies have revealed that uncontrolled
expression of the HPV E6 and E7 oncogenes is responsible
for the ability of HPV to transform cells. While, the func-
tions of the E6 and E7 proteins together can immortalize
human foreskin keratinocytes [3], those of E6 alone can-
not [4]. In addition, the E7 oncogene is more highly con-
served upon viral integration than is E6 [5,6]. The E7
oncogene exerts its transforming function by interrupting
cell differentiation and inducing DNA synthesis [7]. It
accomplishes this by interacting with the cellular tumor
suppressor gene product pRB [8,9]. Additionally, E7 can
induce abnormal centrosome duplication [10,11] and
chromatin condensation [12] possibly leading to chromo-
some instability.
E7 mRNA has been shown to be present in basal layers in
organotypic raft cultures [13], and higher levels have been
found in cervical tumors [14,15]. Few studies [16-19]
have looked for the presence of viral transcripts in precan-
cerous clinical specimens. These studies have shown an
increase in prevalence of HPV E6 and/or E7 mRNA tran-
scripts, and Wang-Johanning et al. [19], in particular,
reported that copy number of both RNA and DNA
increased with increasing SIL grade.
We were interested in determining if any quantitative dif-
ferences existed in the expression of E7 mRNA in cells
from women with normal epithelium and precancerous
lesions. In order to accomplish this goal, we needed to
develop a polymerase chain reaction (PCR) method that
would allow us to make direct comparisons between
patients in terms of amount of mRNA expressed in cervi-
cal specimens. Here, we describe the development of an
absolute quantitative real-time PCR assay to quantitate
mRNA of the E7 oncogene from HPV 16 and HPV 18 in
cervical cytobrush samples.
Results
Absolute quantitation of mRNA
Eighteen cytobrush specimens were analyzed by real-time
PCR for the presence of either HPV16 or HPV18 E7 mRNA
(Table 1). Thirteen samples (87%) showed the presence
of E7 mRNA. The others exhibited no evidence of HPV E7
mRNA in either replicate. Samples 5, 8, and 9 were
included as specificity controls. Samples 5 and 8 were
HPV16 and HPV18 negative but consensus positive by
DNA PCR; sample 9 was negative by all three probes
(HPV16, HPV18, and consensus). All of these samples
produced negative results in the quantitative real-time
PCR; showing that the primers used were specific for
HPV16 or HPV18. As a comparison, the copy numbers of
the control samples (SiHa and HeLa) were calculated in
each reaction. These quantities were then averaged over
the runs to show a mean transcript copy number of 10.9
per 20 ng cDNA for HPV16 in the SiHa samples, and a
mean transcript copy number of 82.6 per 20 ng cDNA for
HPV18 in the HeLa samples. These values are comparable
to previously reported values for SiHa and HeLa. [20,21]
Reproducibility of real time-PCR
Reproducibility of the PCR assay was determined by
repeating the assay on two separate days one week apart.
Since we started the PCR step with the same amount of
total cDNA from each specimen, we were more concerned
with the reproducibility of the PCR step rather than the
Reverse Transcription step. As previously stated, the
Reverse Transcription step was performed separately from
the PCR step to ensure that the quantity of each sample
assayed was equivalent. A one-factor random-effects anal-
ysis of variance was performed to estimate the coefficient
of variation. A coefficient of variation of <20% is consid-
ered adequate for the reproducibility of the assay [22]. All
statistical analyses were performed using Intercooled
STATA 8.2 (Stata Corp., College Station, TX). The coeffi-
cient of variation calculated for this assay was 10.4%.
In addition, the standard curves from each repeated assay
by HPV type were compared utilizing a linear regression
model to fit the threshold cycle (CT) values to variables
representing the natural log of the copy number, the
repeat run number, and an interaction term of the run
number with the natural log of the copy number. This
model allows tests of parallelism and coincidence for the
standard curves from each run. If the p-value from the test
for parallelism is not significant at the α = 0.05 level, then
the regression lines are parallel. Similarly, if the p-value
from the test for coincidence is not significant at the α =
0.05 level, then the regression lines are coincident. The
regression lines for each HPV type were compared sepa-
rately, and there were no significant differences between
them (see Table 2). This can also be seen graphically in
Figure 1. As a result, we are confident that for each HPV
type, the assay itself is reproducible with great accuracy.
Quality of cDNA
To assess the quality of the cDNA for RT-PCR, all negative
samples (n = 5) and a subset of the positive samples (n =
5) were analyzed by real-time PCR using SYBR Green I for
the presence of the G3PDH gene. All samples were posi-
tive for G3PDH; therefore, we are reasonably certain that
the cDNA was of sufficient quality to detect HPV mRNA,
if present.
Discussion
To our knowledge this is only the second report of an
absolute quantitative real-time PCR to measure levels of
HPV mRNA and the first to do so using less expensivePage 2 of 9
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titative PCR by Wang-Johanning et al. utilized a one-step,
Taq-based PCR assay [19]. Our assay differs from theirs in
two ways. First, we used a two-step assay separating the RT
step from the PCR, in this way we were able to measure
the amount of RNA transcript in exactly 20 ng of total
cDNA. Second, our assay utilized the SYBR Green I inter-
calating dye, which allowed us to lower the overall cost of
the assay.
While generally considered more specific, the high cost of
TaqMan-based PCR reactions could be prohibitive for
large-scale molecular epidemiological studies and struc-
tured screening programs. Compared to relative PCR
methods, the use of absolute real-time PCR allows a direct
comparison of the exact copy number of E7 mRNA in
each sample. Other results reported in the literature uti-
lized relative copy numbers in regards to a reference gene,
typically the G3PDH gene. Relative quantitative PCR
reports the number of copies of the gene of interest in rela-
tion to the number of copies of the reference gene present
in the reaction. This helps in identifying the viability of
the sample to produce results; however, the results should
be normalized to an equivalent level of reference gene if
comparisons between samples are to be made. The abso-
lute quantitative PCR reported here allows a direct com-
parison of the copy numbers of the gene of interest
without the need for a reference gene through the con-
Table 2: Comparison of Standard Curves from Real-time PCR Repeat Runs
Run r2 Slope Intercept Efficiency Pparallel Pcoincident
HPV16-1 0.994 -3.386 35.878 97.4% 0.9640 0.8790
HPV16-2 0.997 -3.434 36.290 95.5%
HPV16-3 0.996 -3.450 36.423 94.9%
HPV16-4 0.997 -3.442 36.536 95.2%
HPV18-1 0.966 -2.999 37.714 115.5% 0.8753 0.1479
HPV18-2 0.990 -3.054 35.629 112.5%
Note:
Pparallel tests that the curves are parallel to one another (i.e., they have the same slope)
Pcoincident tests that the curves are coincident (i.e., they have the same slope and y-intercept)
Table 1: Results of Repeated Quantitative Real-time PCR on Cytobrush Specimens
ID HPV type assayed mRNA Log Starting Quantity*** mRNA Copy Number****
Repeat 1 Repeat 2 Repeat 1 Repeat 2
1 16 1.3845 1.409 3.99 4.09
2 16 0 0 0 0
3 16 0.7095 1.026 2.03 2.79
4 16 0 0 0 0
5* 16 0 0 0 0
6 16 1.5385 1.274 4.66 3.58
7 16 1.4075 1.4615 4.09 4.31
8* 16 0 0 0 0
9** 16 0 0 0 0
10 16 1.5605 1.6785 4.76 5.36
11 16 0.737 0.8855 2.09 2.42
12 16 0 0.253 0 1.29
13 16 0.6945 0.656 2.00 1.93
14 16 0.662 0.5 1.94 1.65
15 16 1.35 1.4165 3.86 4.12
16 16 0.468 0.458 1.60 1.58
17 18 0.6625 1.0695 1.94 2.91
18 18 4.2175 4.1265 67.86 61.96
Note: Coefficient of Variation (CV) = 10.4%
*HPV16 and HPV18 negative, HPV consensus positive; used as specificity control
**HPV16, HPV18, and HPV consensus negative; used as specificity control
***Log SQ = ln(copy number)
****per 20 ng cDNAPage 3 of 9
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shown here that the standard curve for the reaction is
highly reproducible and allows accurate comparisons of
HPV E7 mRNA between cytobrush samples.
It is feasible that the detection of high-risk HPV transcripts
could serve as a marker for risk of the development of cer-
vical cancer. It has been shown that E7 promotes the for-
mation of benign lesions while E6 works to complete the
malignant transformation [4]. If the factors that contrib-
ute to the ability of E7 to advance benign lesions were
identified, there might be a way to either identify women
at risk for more intensive screening versus those in whom
the screening process could be minimized. The only other
main viral factor that has been examined as a risk factor
for cervical cancer progression is viral load; however, evi-
dence is still unclear. Most studies associate a high viral
load with high-grade cervical lesions [23-28]; however,
more recent studies suggest that it is a predictor of low-
grade lesions [28-30] and ASCUS [28] as well.
The addition of molecular testing, such as this, to Pap test-
ing could increase the effectiveness of cervical cancer
screening programs by increasing the limited sensitivity
(58%) and specificity (69%) [31] of the Pap test and the
resulting low predictive values of carcinoma. Some
progress has been made with the addition of liquid-based
cytology or HPV DNA testing to conventional Pap testing
[32]. However, simply detecting the presence of viral DNA
is not likely to add as much information as the testing for
viral persistence evidenced by integration and expression
of viral oncogenes. The HPV E7 oncogene is the most con-
served viral gene after integration. Therefore, testing for E7
mRNA, over E6 or E5, could better prove integration has
occurred, the virus is being maintained in the cell, and its
gene products are affecting the cellular replication
machinery. It is this persistent infection that can lead to
the progression of SIL to high-grade lesions and squa-
mous cell carcinoma.
There are several advantages to using real-time PCR for
this purpose. First, typically with cervical sampling very
small amounts of cells or tissue are retrieved. Real-time
PCR can quantitate gene expression from very small
amounts of starting material. Also the ease of the proce-
dure lends itself to use in large-scale epidemiologic stud-
ies where many hundreds of subjects can be analyzed.
Older studies utilizing fluorescent in situ hybridization
and radio-labeled blotting techniques were too labor-
intensive for these large studies [33] and lacked the sensi-
tivity needed to detect the transcripts in low-grade and
normal tissues [34].
Methods to reuse collected material or combine tests
would greatly enhance the yield from cervical samples for
future studies. An example of this is the use of liquid-
based cytology to perform Pap smears, after which the
cells are available for HPV typing [35]. In addition, con-
tinuing efforts to improve the reliability of multiplex real-
time PCR reactions will allow the testing of multiple HPV
types in one assay. This would further decrease the
amounts of cellular material needed for these studies. This
is extremely important in the cervix where few viable cells
are collected during sampling.
Conclusion
In summary, we present here the methods used to develop
an absolute quantitative real-time PCR for the measure-
ment of expression of viral oncogenes. We showed previ-
ously that this method could be utilized in a high-
throughput manner to assess HPV E7 expression in clini-
cal samples[36]. The ability to directly measure these
oncogenes could facilitate the discovery of markers that
predict cervical progression. The main goal of this type of
research is to hone the screening capabilities for HPV-
related carcinoma. Several suggestions have been made as
additional markers to include in cervical cancer screening
(HPV typing, HPV viral load, etc.); however, much
Comparison of Standard Curves from Repeated Assays by HPV TypeFigure 1
Comparison of Standard Curves from Repeated Assays by 
HPV Type. This figure is a graphical comparison of the stand-
ard curves from each of the HPV 16 and HPV 18 assays. 
There were four assays performed for HPV 16 and two for 
HPV 18. The type-specific curves were not statistically differ-
ent from one another, and those for HPV 16 are graphically 
identical. (Note: ln(SQ) = natural log of starting quantity.)Page 4 of 9
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tive and specific screening program.
Methods
Cervical samples
Cervical specimens were collected as part of a larger study
to evaluate emerging optical technologies for cervical neo-
plasia. The study population consisted of women with
abnormal Pap test results attending the colposcopy clinics
at The University of Texas M. D. Anderson Cancer Center,
Lyndon B. Johnson General Hospital, and Memorial Her-
mann Hospital in Houston, Texas, USA, and the British
Columbia Cancer Agency in Vancouver, British Colum-
bia, Canada, between October 2000 and July 2003. IRB
approval was received from each institution involved in
the study, and participants gave written informed consent
prior to being enrolled in the study.
Clinical specimens were collected for various laboratory
procedures, including: histopathologic confirmation of
disease, quantitative cyto- and histopathology, HPV typ-
ing, and HPV DNA and mRNA analyses. Study physicians
collected specimens for HPV DNA and RNA analyses
using an endocervical cytobrush. Specimens for DNA
extraction were placed in 250 μl PBS with 0.02% sodium
azide immediately following cytologic sampling and
stored at -80°C until extracted, approximately one month
after collection. Specimens for RNA extraction were
placed in 250 μl of lysis buffer (Ambion, Austin, TX)
immediately following cytologic sampling, and stored at -
80°C until extracted; length of storage varied from 5
months to 3 years after collection. To assess the quality of
the mRNA, the concentration of all mRNA samples was
measured by spectrophotometry, and all cDNA samples
were assayed for G3PDH by real-time PCR. All samples
were measurable by both methods.
Cell lines
The cervical cancer cell lines HeLa and SiHa were pur-
chased from American Type Culture Collection (Manas-
sas, VA) for use as positive controls in the reactions. HeLa
cells express HPV 18 mRNA, and SiHa cells express HPV
16 mRNA. Both cell lines were grown in Eagle's Minimal
Essential Medium (EMEM) with 10% fetal bovine serum
and penicillin-streptomycin. The cells were incubated at
37°C in a 5% CO2 atmosphere and harvested directly in
lysis buffer (Ambion, Austin, TX). Total mRNA was iso-
lated from the harvested cells using the same kit used for
the patient samples (RNAqueous, Ambion, Austin, TX),
and cDNA was similarly generated (RETROScript,
Ambion, Austin, TX) (see section RNA extraction and
reverse transcription).
DNA isolation and detection
Viral DNA was extracted from cervical cytobrush speci-
mens using a commercially available kit (QIAamp DNA
Mini Kit, Qiagen, Valencia, CA, USA) according to manu-
facturer's buccal swab spin protocol. To maximize DNA
yield from the cervical samples, all 250 μl of lysate was
used for DNA extraction. Briefly, 20 μl of Proteinase K and
400 μl of Buffer AL was added to the tube containing the
specimen. The reaction was incubated at 56°C for 10 min-
utes, and 400 μl of ethanol was added to the tube and vor-
texed to mix. Immediately prior to elution of the DNA, the
cytobrushes were removed from the tubes by using for-
ceps, which were flamed between each use to prevent con-
tamination. The cytobrush was left in the tube up to this
point to harvest as much of the DNA as possible from the
Standard Curve from HPV 16 E7 AssayFigure 2
Standard Curve from HPV 16 E7 Assay. This figure represents the standard curve of the HPV 16 PCR. Note, the standard dilu-
tions appear as blue circles on the graph, and the unknown samples appear as red squares. The calculated regression line of the 
curve is given above the graph. In this case, Y = -2.882X + 34.568. Setting Y equal to the CT for the unknown, solving for X will 
give the starting quantity for the unknown sample.Page 5 of 9
(page number not for citation purposes)
Infectious Agents and Cancer 2007, 2:8 http://www.infectagentscancer.com/content/2/1/8sample. This mixture was applied in two steps to the
QIAamp Spin Column and centrifuged at 8,000 rpm for 1
min after each application. The spin column was washed
with 500 μl of Buffer AW1 and AW2, centrifuging for 1
min at 8,000 rpm and 3 min at 14,000 rpm, respectively.
Any fluid was removed from the collection tube and the
column was centrifuged for 1 min at 14,000 rpm to
remove any residual fluid and dry the filter. The filter was
placed in a clean microcentrifuge tube, and 110 μl of
Buffer AE was added to the filter. This was incubated at
room temperature for 5 min, and then eluted by centrifug-
ing for 1 min at 8,000 rpm. Extracted DNA was stored at -
80°C for no more than 4 weeks before PCR was per-
formed.
Following the methods of Manos et al. [37], we then ana-
lyzed the samples for HPV DNA using MY9 and MY11
consensus HPV primers that amplify a 450 base pair
region of the L1 open reading frame of at least 28 different
HPV types. PCR products were resolved by agarose gel
electrophoresis, transferred to nylon membranes (Bio-
Rad Laboratories, Hercules, CA), and hybridized to a 32P-
labeled HPV consensus probe. Consensus probe-positive
samples were then hybridized to 32P-labeled specific HPV
16 and HPV 18 probes on separate nylon membranes.
Sample positivity was assessed by autoradiography fol-
lowing hybridization. DNA extracted from HPV 18-posi-
tive HeLa cells, HPV 16-positive CaSki cells, and a
negative control without DNA were used as controls in all
the PCRs and subsequent hybridizations.
RNA extraction and reverse transcription
RNA was extracted as total mRNA from cervical cytobrush
specimens using a commercially available kit (RNAque-
ous, Ambion, Austin, TX). To increase the mRNA yield, all
250 μl of the lysate was used for mRNA extraction. Briefly,
125 μl of 100% ethanol was added to the sample tube,
which was then briefly vortexed and centrifuged. The cyto-
brushes were then removed from the tubes after ethanol
treatment by using forceps, which were flamed between
each use to prevent contamination. The lysate mixture was
loaded in 150-μl aliquots onto a Micro Filter Cartridge
tube and centrifuged to pass the solution over the filter.
This was repeated until all of the lysate was passed
through the filter. Wash solutions (1 and 2/3) were added
to the filter, and the tube was centrifuged between each
wash. Any fluid was removed from the collection tube,
and the filter was centrifuged for 1 min to remove any
residual fluid and dry the filter. The filter was placed in a
clean Micro Elution tube, and the RNA was eluted into a
total of 20 μl of elution solution heated to 75°C in 2
steps, centrifuging at each step. Treatment with DNase I
was done according to kit instructions to remove any trace
amounts of contaminating genomic DNA. Following
inactivation of the DNase, the tube was centrifuged for 2
min, and the pellet was left in the tube, which was then
stored at -80°C.
For the expressed purposes of analyzing the same amount
of cDNA in every specimen, reverse transcription was per-
formed as a separate step from PCR. The mRNA was then
reverse transcribed into cDNA (RETROscript, Ambion,
Austin, TX) on the same day as the extraction. Briefly, 3 μl
of random decamers (provided in kit) was added to 15 μl
of the RNA elution mixture. A final reaction volume of 30
μl was achieved with the addition of 3 μl 10× RT Buffer, 6
μl dNTP mix, 1.5 μl RNase Inhibitor, and 1.5 μl reverse
transcriptase (all provided in kit). The reaction was vor-
texed briefly and incubated at 50°C for 1 hr. The tubes
were then heated at 92°C for 10 minutes to inactivate the
reverse transcriptase. To obtain the highest yield of cDNA,
the incubation step was optimized at 50°C (from the
standard 44°C) per the recommendation of the manufac-
turer. The cDNA samples were then purified using NucA-
way Spin Columns (Ambion, Austin, TX) to remove
unused dNTPs and any other DNA or RNA material <25
bases in length. The concentration of the cDNA was deter-
mined in a spectrophotometer at 260 nm on the same day
it was generated, and the cDNA was stored at -80°C for no
more than 1 month prior to analysis by real-time PCR.
Absolute real-time PCR
To perform an absolute quantitative real-time PCR, plas-
mids constructed with specific binding sites for HPV 16
and HPV 18 E7 primers were used to derive the standard
curves (Figure 2) for each set of patient samples that were
assayed [38]. Reactions were carried out for HPV 16 and
HPV 18 separately, and each experiment had its own
standard curve. The following primers were used for con-
struction of the HPV 16 E7 and HPV 18 E7 internal stand-
ard with human glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) cDNA as a template. These
primers contained 24 bases of HPV 16 or 18 E7 sequence
(shown as capital letters) and 20 bases of G3PDH
sequence (shown as lower-case letters).
HPV 16:5'-ATGACAGCTCAGAGGAGGAGGATGacggattt-
ggtcgtattggg-3'
5'-CAGATGGGGCACACAATTCCTAGTtgattttggag-
ggatctcgc-3'
HPV 18:5'-CACGAGCAATTAAGCGACTCAGAGacggattt-
ggtcgtattggg-3'
5'-ATGCAGACCACGGACACACAAAGGtgatttggag-
ggatctcgc-3'
PCR was performed using these primers and G3PDH
cDNA as a template. The resulting PCR products con-Page 6 of 9
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end of a 278 G3PDH base pair product. These PCR prod-
ucts were then reamplified using the same HPV sequences
used in the first round of PCR, but without the G3PDH
sequences. The resulting products, one for HPV 16 E7 and
one for HPV 18 E7, were ligated into a pCRII plasmid
(Invitrogen, San Diego, CA). Sequence analysis of the two
recombinant plasmids confirmed that the HPV sequences
were correctly attached at the end of the G3PDH frag-
ment. The utility of the plasmid is two fold: to perform
absolute quantitative PCR from a standard curve based on
copy number, and to have the ability to multiplex HPV
and G3PDH in the same reaction, although this was not
done for the current study.
A set of serial dilutions of the HPV E7-containing plas-
mids (1 × 108, 1 × 105, 1 × 104, 1 × 103, 1 × 102, 1 × 101,
1 × 100 copies/μl) was used as PCR templates for the
standard curve. Each standard dilution was tested in trip-
licate, and each patient sample was tested in duplicate
(due to the minimal yield of the mRNA extraction proc-
ess). Positive (SiHa for HPV 16 and HeLa for HPV 18) and
negative controls were included in each experiment to
ensure reproducible results.
The PCR technique used in this study was an absolute
quantitative real-time PCR assay using the SYBR Green I
(Molecular Probes, Eugene, OR) fluorescent intercalation
dye. Each amplification experiment was performed in a
96-well PCR plate covered with optical tape in the iCycler
iQ real-time PCR instrument (Bio-Rad Laboratories, Her-
cules, CA). A final volume of 25 μl was used containing 20
ng of cDNA template, 12.5 μl of iQ SYBR Green Supermix
(Bio-Rad Laboratories, Hercules, CA), 1.25 μl containing
0.2 micromoles of either HPV 16 or HPV 18 forward and
reverse primers, and water. Primers used for HPV 16 E7
PCR were 5'-atgacagctcagaggaggaggatg-3' and 5'-cagat-
ggggcacacaattcctagt-3'. They were designed to amplify a
196 bp fragment of HPV 16 E7 cDNA (nt 647-nt 842).
Primers for HPV 18 E7 PCR were 5'-atgcagaccacg-
gacacacaaagg-3' and 5'-cacgagcaattaagcgactcagag-3' which
amplified a 226 bp fragment of HPV 18 E7 cDNA (nt 671-
nt 896). A BLAST search of the primers used for HPV 16
E7 showed alignment with all major variants of HPV 16
(AA, Af1, Af2, As, and E). There is less information in the
NCBI database on HPV 18 since it is much less frequent
than HPV 16. A BLAST search of the primers used for HPV
18 E7 showed alignment with HPV 18 sequences; how-
ever, the variant specificity was not available. Although
variant-specific sequences for HPV 18 were not available
for comparison, it has been shown that the E6 and E7
genes of the high-risk HPVs are highly conserved among
viral types and would therefore, be highly conserved
among the variants within the types. [39] We, therefore,
do not expect that variants of HPV 18 would cause prob-
lems in quantifying the E7 gene in our samples. Reaction
contamination by exogenous HPV DNA or RNA was ruled
out by the inclusion of a reaction tube containing all rea-
gents but no sample cDNA. The reaction was subjected to
denaturation at 95°C for 2 minutes followed by 40 cycles
of denaturation at 95°C for 45 seconds, annealing at
62°C for 45 seconds, and elongation at 72°C for 45 sec-
onds. Fluorescent data were specified for collection at the
end of the elongation step in each cycle. SYBR Green I
binds and intercalates into double-stranded DNA during
the extension step of the amplification cycle.
An equal quantity of cDNA (20 ng) from each sample was
analyzed by real-time PCR for quantitation of HPV 16 and
HPV 18 E7 oncogene expression (cDNA levels reflect
mRNA levels). Using the same amount of total cDNA (20
ng) from each sample allows for accurate comparison of
the target mRNA between the samples independent of
amount of sample collected and independent of the effi-
ciency of the RT step. This was the purpose of carrying out
the two-step real-time PCR. All study participants were
identified as positive for HPV 16 and/or HPV 18 DNA by
PCR. Three additional samples that were HPV16 and
HPV18 DNA negative, but two were positive by consensus
hybridization and one negative by consensus hybridiza-
tion. These samples were included to test the viral type
specificity of the assay. Samples were analyzed by real-
time PCR according to the DNA results for each specimen.
For example, if the sample was positive for HPV 16 DNA
and negative for HPV 18 DNA, real-time PCR was done
using only the HPV 16 primers.
A similar SYBR Green I real-time PCR technique, as
described above, was used to identify the presence of the
G3PDH gene to determine quality of the cDNA in the
clinical samples used for quantification of HPV E7. For
each amplification experiment, a final volume of 25 μl
was used containing 2 μl of cDNA template, 12.5 μl of iQ
SYBR Green Supermix (Bio-Rad), 1.25 μl containing
0.176 micromoles of G3PDH forward and reverse prim-
ers, and water. Primers used for G3PDH were 5'-acggattt-
ggtcgtattggg-3' and 5'-tgattttggagggatctcgc-3'. They were
designed to amplify a 230 bp fragment of G3PDH cDNA.
The reaction was subjected to denaturation at 95°C for 2
minutes followed by 40 cycles of denaturation at 95°C for
30 seconds, annealing at 51°C for 30 seconds, and elon-
gation at 72°C for 60 seconds. The presence of G3PDH in
a sample indicated that we were able to get amplifiable
product from that specimen; in this manner G3PDH was
used as a quality control for each sample.
Calculation of copy number from standard curve
The software with the PCR instrument calculates the
standard curve for each run based on the CT for each
standard (see Figure 2). Based on these values, a linearPage 7 of 9
(page number not for citation purposes)
Infectious Agents and Cancer 2007, 2:8 http://www.infectagentscancer.com/content/2/1/8regression line is plotted and the resulting equation is
used to calculate the log starting quantity and copy
number for the unknown clinical samples.
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